27 Dec 2017 17:45
REDX PHARMA PLC
("Redx" or "the Company")
Share Purchases by Directors
Alderley Park, December 27 2017- Redx Pharma (AIM:REDX), the drug discovery and development company, announces that it has been notified that Iain Ross, Executive Chairman, has on Friday 22 December acquired 102,000 Redx ordinary shares at a price of 20.75 pence per share. Following this, Mr Ross will hold 450,000 ordinary shares in the Company, representing 0.36 per cent. of the issued share capital.
The Company also announces that Non-Executive Director Mr Peter Presland has on Friday 22 December acquired 120,000 Redx ordinary shares at a price of 22 pence per share. Mr Presland purchased the shares through his self-invested personal pension (SIPP). Following this, Mr Presland will hold 120,000 ordinary shares in the Company, representing 0.09 per cent of the issued share capital.
The Company also announces that Non-Executive Director Dr Bernhard Kirschbaum has today acquired 50,000 Redx ordinary shares at a price of 21 pence per share. Following this, Dr Kirschbaum will hold 50,000 ordinary shares in the Company, representing 0.04 per cent of the issued share capital.
For further information, please contact:
Redx Pharma Plc | T: +44 1625 469 918 |
Iain Ross, Executive Chairman | |
Cantor Fitzgerald Europe (Nominated Advisor & Broker) | T: +44 20 7894 7000 |
Phil Davies |
|
| |
WG Partners LLP (Joint Broker) | T: +44 20 3705 9330 |
Claes Spång/ Chris Lee/ David Wilson |
|
FTI Consulting | T: +44 20 3727 1000 |
Simon Conway/Stephanie Cuthbert |
|
About Redx Pharma
Redx Pharma discovers and develops proprietary, small molecule drugs to address areas of high unmet medical need in cancer and fibrosis. In cancer, Redx pursues targeted therapies where a biomarker can potentially be used for selecting those patients that are most likely to benefit from therapy, and/or drugs that are designed to disrupt cancer resistance pathways. In fibrosis, the Company is focused on developing treatments that will stop and reverse the formation of fibrotic tissue. In both therapeutic areas Redx's aim is to develop drugs whose profile suggests they will be best in class, if not first in class.
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | ||
1 | Details of the person discharging managerial responsibilities/person closely associated | |
a. | Name | Iain Ross |
2 | Reason for notification |
|
a. | Position/Status | Executive Chairman |
b. | Initial notification/ Amendment | Initial Notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a. | Name | Redx Pharma Plc |
b. | LEI | 213800HMS4EBXO589Y37 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a. | Description of the financial instrument, type of instrumentIdentification Code | Ordinary Shares of 1p each ISIN: GB00BSNB6S51 |
b. | Nature of the transaction | Purchase |
c. | Price(s) and volume(s) | 102,000
20.75 pence |
d. | Aggregated information - Aggregated Volume - Price | N/A - Single Transaction |
e. | Date of the transaction | 22/12/17 |
f. | Place of the transaction | Outside of trading venue |
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | ||
1 | Details of the person discharging managerial responsibilities/person closely associated | |
a. | Name | Peter Presland |
2 | Reason for notification |
|
a. | Position/Status | Non-executive Director |
b. | Initial notification/ Amendment | Initial Notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a. | Name | Redx Pharma Plc |
b. | LEI | 213800HMS4EBXO589Y37 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a. | Description of the financial instrument, type of instrumentIdentification Code | Ordinary Shares of 1p each ISIN: GB00BSNB6S51 |
b. | Nature of the transaction | Purchase |
c. | Price(s) and volume(s) | 120,000
22 pence |
d. | Aggregated information - Aggregated Volume - Price | N/A - Single Transaction |
e. | Date of the transaction | 22/12/17 |
f. | Place of the transaction | Outside of trading venue |
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | ||
1 | Details of the person discharging managerial responsibilities/person closely associated | |
a. | Name | Bernhard Kirschbaum |
2 | Reason for notification |
|
a. | Position/Status | Non-executive Director |
b. | Initial notification/ Amendment | Initial Notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a. | Name | Redx Pharma Plc |
b. | LEI | 213800HMS4EBXO589Y37 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a. | Description of the financial instrument, type of instrumentIdentification Code | Ordinary Shares of 1p each ISIN: GB00BSNB6S51 |
b. | Nature of the transaction | Purchase |
c. | Price(s) and volume(s) | 50,000
21 pence |
d. | Aggregated information - Aggregated Volume - Price | N/A - Single Transaction |
e. | Date of the transaction | 27/12/17 |
f. | Place of the transaction | Outside of trading venue |